Alveus: Best-in-class opportunity in obesity
Obesity company closes capital raising of DKK 1.2 billion – brings Novo Holdings on board
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: “I sidste ende føles det helt rigtigt”
Equipped with $160M series A, Alveus debuts into crowded obesity development landscape
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Obesity biotech Alveus gains $160M for push into MariTide’s backyard — and amylins
Alveus Therapeutics exits stealth with $160M, developing an alternative to drugs like Ozempic
$160 million Series A round for Alveus
Biotech Alveus raises $160 million to tackle weight loss maintenance